Literature DB >> 23314727

Novel pharmacologic therapies in development for acute decompensated heart failure.

Justin A Ezekowitz1.   

Abstract

Acute heart failure is a public health issue with morbidity and mortality exceeding that of myocardial infarction. Novel compounds for the treatment of acute heart failure are clearly needed and fall into the general categories of inotropic, vasodilatory and other compounds in phase I to III of development. Furthest along are omecamtiv mecarbil (a cardiac myosin activator), ularitide (a natriuretic and diuretic peptide) and relaxin (a vasodilator). Each compound has a unique set of assets and liabilities that will aid in the understanding of the syndrome and application to the right patients at the right time in this heterogeneous syndrome. This review will explore current and future novel pharmacologic therapies for the treatment of acute heart failure.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23314727     DOI： 10.1007/s11886-012-0329-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  37 in total

1.  Design of the RELAXin in acute heart failure study.

Authors:  Piotr Ponikowski; Marco Metra; John R Teerlink; Elaine Unemori; G Michael Felker; Adriaan A Voors; Gerasimos Filippatos; Barry Greenberg; Sam L Teichman; Thomas Severin; Guenther Mueller-Velten; Gad Cotter; Beth A Davison
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

2.  Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.

Authors:  Erland Erdmann; Marc J Semigran; Markku S Nieminen; Mihai Gheorghiade; Rahul Agrawal; Veselin Mitrovic; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2012-07-09       Impact factor: 29.983

Review 3.  The vascular actions of relaxin.

Authors:  Arundhathi Jeyabalan; Sanjeev G Shroff; Jaqueline Novak; Kirk P Conrad
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

4.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

5.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

6.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Authors:  John G F Cleland; John R Teerlink; Roxy Senior; Evgeny M Nifontov; John J V Mc Murray; Chim C Lang; Vitaly A Tsyrlin; Barry H Greenberg; Jamil Mayet; Darrel P Francis; Tamaz Shaburishvili; Mark Monaghan; Mitchell Saltzberg; Ludwig Neyses; Scott M Wasserman; Jacqueline H Lee; Khalil G Saikali; Cyril P Clarke; Jonathan H Goldman; Andrew A Wolff; Fady I Malik
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

7.  Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.

Authors:  Mihai Gheorghiade; Stephen J Greene; Gerasimos Filippatos; Erland Erdmann; Roberto Ferrari; Phillip D Levy; Aldo Maggioni; Christina Nowack; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2012-06-19       Impact factor: 15.534

8.  Testosterone therapy in women with heart failure "why can't a woman be more like a man?".

Authors:  Paul W Armstrong; Justin A Ezekowitz
Journal:  J Am Coll Cardiol       Date:  2010-10-12       Impact factor: 24.094

9.  Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.

Authors:  Mihai Gheorghiade; John E A Blair; Gerasimos S Filippatos; Cezar Macarie; Witold Ruzyllo; Jerzy Korewicki; Serban I Bubenek-Turconi; Maurizio Ceracchi; Maria Bianchetti; Paolo Carminati; Dimitrios Kremastinos; Giovanni Valentini; Hani N Sabbah
Journal:  J Am Coll Cardiol       Date:  2008-04-09       Impact factor: 24.094

Review 10.  End points for clinical trials in acute heart failure syndromes.

Authors:  Larry A Allen; Adrian F Hernandez; Christopher M O'Connor; G Michael Felker
Journal:  J Am Coll Cardiol       Date:  2009-06-16       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.